Talisman develops disease-modifying therapeutics for Alzheimer's and other neurodegenerative diseases. We also provide access to our revolutionary iPSC platform to support external R&D partnerships.
Talisman has built a best-in-class human neuroscience discovery platform, combining human stem cell-derived neural cell types with human genetics to engineer models of disease initiation and progression. Our iPSC technology transforms the discovery of disease-modifying treatments by avoiding the limitations of current neurological drug discovery approaches.
We apply our human discovery platform to every stage of preclinical development, from novel target ID to clinical candidate selection. Our internal discovery programs are focussed in three areas: lysosome biology, pathogenic protein reduction and microglial health.
Talisman has supported the neuroscience preclinical discovery programs of biotechs, company-creating VCs and global pharma for over 10 years. Learn more about our expertise and how Talisman can accelerate progression of your preclinical neuroscience portfolio.
As part of our compliance in relation to the General Data Protection Regulations 2019 (GDPR) please find below our Job Applicant Privacy Notice. Please be reassured that any application will be managed in accordance with this Notice.
Applicant Privacy Notice
